Tyra Bioscience, Inc (TYRA)

In August 2025, Tyra Biosciences announced the first child dosed in its Phase 2 study for dabogratinib and participated in investor events. In September 2025, the company participated in the H.C. Wainwright 27th Annual Global Investment Conference. In November 2025, Tyra Biosciences reported its Third Quarter 2025 financial results, posting an EPS of -$0.50, exceeding expectations, and the stock increased significantly and the company announced participation in upcoming investor events. In December 2025, Tyra Biosciences appointed a Chief Operating Officer and Chief Regulatory Officer and participated in healthcare conferences. In January 2026, the stock hit 52-week and all-time highs, analyst price targets were raised, and the Chief Discovery Officer reported preset insider stock sales. In February 2026, Tyra Biosciences received an investment bank analyst rating update, and the stock price gained 5.23% on February 6, 2026.

As a clinical-stage biotechnology company, Tyra Biosciences does not have commercialized products or services that would exhibit traditional demand seasonality. Its demand is primarily driven by investor interest, progress in its clinical pipeline, and regulatory milestones.

Tyra Biosciences is a clinical-stage biotechnology company focused on developing next-generation precision medicines using its proprietary SNÅP platform to design highly selective, oral small molecules. Their lead product candidate, TYRA-300 (dabogratinib), is being developed for various conditions, including pediatric achondroplasia and urothelial carcinoma. TYRA-200 is in clinical trial for bile duct and solid tumors and TYRA-430 is being developed for the treatment of hepatocellular carcinoma. As a clinical-stage company, Tyra Biosciences does not yet generate product revenue.

Tyra Biosciences is headquartered in Carlsbad, California, United States, with operations and clinical trials primarily focused within the United States.

Tyra Biosciences generally holds a positive brand reputation within the investment community, with a consensus rating of "Buy" or "Moderate Buy" from analysts. Positive events impacting its reputation include positive earnings reports, advancements in clinical trials, expansion of dabogratinib's development, strengthening of the leadership team, and multiple analyst price target increases. There were no significant negative events impacting Tyra Biosciences' reputation within the past year.

Tyra Biosciences has significant institutional ownership, with 234 institutional owners and shareholders holding approximately 62.08% of shares. Major institutional owners include Ra Capital Management, L.P., Nextech Invest, Ltd., and Alta Partners Management Company, L.P. Individual ownership includes the CEO, Todd Harris, who directly owns 2.54% of the company's shares.